Avacta Share Discussion Threads

[amanitaangelicus] 01/7/2024 13:18

I think i won that one Raj. If u could read a chart it might help.Volume generally up..Loadsa fake price setting going on..ps well done on your 8 upticks. The dim love a trader.

[rajraj b] 01/7/2024 08:31

Could very easily reverse from here and continue up. CLN could possibly be paid in cash. Don't want to get left behind. Just trying to help as well.

[amanitaangelicus] 01/7/2024 07:35

Gone up too fast, probs needs to drop back to 50p ...you don't wanna get spiked. Just trying to help.

[amanitaangelicus] 01/7/2024 07:33

Certainly turned ...hopefully it can continue. Not holding but watching with interest

[baldrick1] 28/6/2024 13:19

Almost breakeven on my charity holdings could be some good news for the cancer patients in the near future.

[fieldhouse] 28/6/2024 12:50

“He who hesitates is lost”

[sos100] 28/6/2024 12:48

very strong ...I think this will be over 60p soon

[amanitaangelicus] 28/6/2024 09:42

Booooooooom! What gives? Good turnaround. Watching with interest.

[millennialinvestor] 28/6/2024 09:13

I think when a patient is riddled with cancer, It's frowned upon to say they have 12 months to live and then they die the following week.

Common practice to lower expectations and say they have 3 months to live.

[fieldhouse] 28/6/2024 07:28

Rajraj b

Very well explained.It’s all there for those that want to see

[hey50] 28/6/2024 01:23

I bought into this company because of the ground breaking work they've been doing for cancer. Having had my most beloved go through it twice, I just hope there is an end!COVID just fu@ked everything for everyone so. Let's move forward

[rajraj b] 28/6/2024 01:01

Jak, you must remember that the patients used in cohorts C1-C7 were end of life patients. They had a variety of cancers that were either unreactive to doxorubicin, immune to doxorubicin or developed tolerance to doxorubicin due to over use. These cancers had also developed methods to protect themselves from the therapeutic effects of chemo in general. Basically, the investigators were not expecting to see ANY efficacy in these participants. The fact that some of them have shown physical signs of tumour shrinkage and a number of them are still alive after nearly 2 years ( they were not expected to last a few months) is quite remarkable. You can look at these percentages of efficacy in any skewered way you like but it still won't change the fact that that they have helped some patients who were given NO chance of survival. Now give AVA6000 to patients who have cancers that are specifically receptive to Doxorubicin and are chemo virgin will really show what this drug is all about. To keep saying the P1a trial has shown only 5% efficacy and hence 95% failure is pretty misleading. Remember these patients should all be dead. Why are any of them still alive?

[rajraj b] 27/6/2024 16:22

A great post by Jive Turkey on LSE - Comparison with ADCsToday 15:32 As anyone who has listened to CC's presentations over the last couple months (including yesterday) will know, she has put a huge amount of emphasis on the fact that they see a 2-log difference (i.e., 100x) between the concentration of dox in the tumour vs. in the plasma, the so called tumour-to-plasma ratio. While this sounds very impressive, I've been lacking a bit of enthusiasm for this, because we were never given a comparator. i.e., if standard dox was used what would this ratio be? Apparently this has never been published for straight dox. This has been measured, however, for a number of ADCs. ADCs, as we know, are the bees knees in modern oncology treatment, because they allow specific targeting of a warhead to the tumour. Because they are more specific, much more cytotoxic warheads can be used. So what is the tumor-to-plasma ratio for ADCs at 24 hours? T-DM1 (Trastuzumab Emtansine): In clinical studies involving T-DM1, a tumor-to-plasma concentration ratio of approximately 3:1 to 5:1 was observed within 24 hours after administration. Brentuximab Vedotin (Adcetris): Another ADC, Brentuximab Vedotin, targeting CD30-positive lymphomas, has demonstrated tumor-to-plasma concentration ratios in a similar range, often around 4:1 to 8:1. So, at least for these two ADCs, the ADC is around 3-8 times more concentrated in the tumour than in the blood. Ava6k blows this out of the f'ing water. 100 to 1 with Precision. This is what Avacta are sitting on.So Jak, you can put that in your pipe and smoke it!!

[robers98] 27/6/2024 15:29

Further movement today following the AGM led by the new management team.

[1347] 27/6/2024 15:03

Nah, it's just the next death spiral payday loan conversion being forward sold. MMs are duly obliging.

[divmad] 27/6/2024 14:36

The 50s coming into sight at long last. All thanks to the new CEO, Chairman and ex-FD, with a little thanks to AV6k working its magic still.

[millennialinvestor] 27/6/2024 11:18

AVA6000, world leading tumor growth drug. 95% effective!

[fieldhouse] 27/6/2024 10:54

Get a job and do some work

[millennialinvestor] 27/6/2024 10:51

In my humble opinion I think AVA6000 is more of a tumor fertiliser than anything.

[fieldhouse] 27/6/2024 10:50

Do proper research

[millennialinvestor] 27/6/2024 10:38

Using the logic that the data shows tumor shrinkage in 5% of patients...

That means that in this data there must be statistics for % of patients that showed tumor GROWTH using AVA6000?

[fieldhouse] 27/6/2024 10:35

+ Are you part of the international crime organisation disrupting western democracy ?
SCAM

[fieldhouse] 27/6/2024 10:24

The platform dear boy ,all about the platform that can deliver many variations .

Any how, why are you know all’s not at work with a productive job ?

Like about half the country lazy and obese (fat)

[1347] 27/6/2024 10:24

"So no dose limiting toxicities observed as of yet."

"So it’s non toxic up up to now in the 2 week trial and now we’re dosing on cohort 3"

You need to read that properly. "no dose limiting toxicities" is NOT the same thing as "it's non-toxic".

I've said all along that any reduction in toxicity of Dox is a good thing, but Avacta have not yet established what the effect on efficacy is, until they do so then all they've proven is that it's safe enough to go on to the next phase. It's taken them 3 years to do that for one candidate! Poor execution!